Storys zum Thema Health

Folgen
Keine Story zum Thema Health mehr verpassen.
Filtern
  • 30.03.2022 – 15:00

    Debiopharm International SA

    VIVOSENSE ANNOUNCES CLOSING OF $25M SERIES A FINANCING

    Newport Beach (ots) - Proceeds to accelerate the collection and use of wearable sensor data in clinical trials along with the development of novel digital biomarkers Funding round co-led by the Perceptive Xontogeny Venture (PXV) Fund and Switzerland-based Debiopharm Innovation Fund VivoSense, Inc., (“VivoSense”) an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor ...

  • 30.03.2022 – 14:01

    Lumanity

    Lumanity Acquires Innovative Edge

    New York (ots/PRNewswire) - Creating an end-to-end pharmaceutical product commercialization and launch excellence capability that optimizes and accelerates patient access to medical advances Lumanity today announced the acquisition of Innovative Edge ("IE"), a leading provider of pharmaceutical product launch services. The terms of the transaction were not disclosed. IE partners with world-leading biopharma companies – from Top 20 pharmaceutical manufacturers to ...

  • 28.03.2022 – 13:35

    Abcam plc

    Abcam the most awarded company at 2022 industry awards

    Cambridge, England (ots/PRNewswire) - CAMBRIDGE, England, March 25, 2022 Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards, the highest of any participant evaluated this year. This record number of acknowledgments follows a year of substantial investment for Abcam to enable life sciences researchers from academia and industry to advance ...

  • 25.03.2022 – 14:22

    Abcam

    Abcam the most awarded company at 2022 industry awards

    Cambridge, England (ots/PRNewswire) - CAMBRIDGE, England, March 25, 2022 Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards, the highest of any participant evaluated this year. This record number of acknowledgments follows a year of substantial investment for Abcam to enable life sciences researchers from academia and industry to advance ...

  • 24.03.2022 – 08:00

    MoonLake Immunotherapeutics AG

    MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint

    Zug, Switzerland (ots/PRNewswire) - - This Phase 2 study represents an important step in hidradenitis suppurativa ("HS") clinical development, as it will be the first to use the higher clinical response level of HiSCR75 as the primary endpoint - Expected to enroll over 200 patients with moderate-to-severe HS to ...